Urinary exosomal prostate‐specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles
International Journal of Cancer · 15.04.2023 · 152 (8) · 1719-1727
DOI: 10.1002/ijc.34388 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, online erschienen am 12.12.2022. Verfasst von Chunmeng Wei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center f…. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Major Project of Guangxi.
Abstract (Originalsprache)
The study aimed at evaluating the performance of urinary exosomal prostate‐specific antigen (UE‐PSA) to predict the results of initial prostate biopsies and discriminate clinically significant prostate cancer (Gleason score ≥ 7, csPCa) from nonsignificant PCa (Gleason score < 7, nsPCa) plus benign patients. Two hundred seventy‐two consecutive participants were admitted who underwent a prostate biopsy. The UE‐PSA expression was detected by enzyme‐linked immunosorbent assay (ELISA). The predictive power and clinical value of UE‐PSA was assessed by receiver operating characteristic (ROC), decision curve analysis (DCA) and waterfall plots. UE‐PSA was upregulated in PCa compared to benign patients ( P < .001) and csPCa compared to nsPCa plus benign patients ( P < .001). UE‐PSA achieved an AUC of 0.953 (0.905‐0.989) in distinguishing PCa from benign patients and an AUC of 0.879 (0.808‐0.941) in predicting csPCa from nsPCa plus benign patients. These results were validated in an additional multicenter cohort. In addition, DCA showed that UE‐PSA achieved the highest net benefit at almost any threshold probability compared to tPSA and %fPSA. As the waterfall plot showed, the UE‐PSA assay could avoid 57.6% (155 cases) and 34.6% (93 cases) unnecessary biopsies while only missing 2.6% (7 cases) and 1.5% (4 cases) of the cases of csPCa at the cutoff value of 90% and 95% sensitivity, respectively. We validated that UE‐PSA presented great diagnostic power and clinical utility to diagnose PCa and csPCa. UE‐PSA could be a promising noninvasive biomarker to improve PCa detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nann…
- Department of Urology, Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
- School of Public Health, Guangxi Medical University, Nanning, Guangxi, China.
- Department of Urology, No. 971 Hospital of the People's Liberation Army Navy, Qingdao, China.
- Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
ORCID-Profile: Jin Ji, Zengnan Mo, Fubo Wang
Förderung
- National Natural Science Foundation of China
- Science and Technology Major Project of Guangxi
Zitieren
APA
Wei, C., Chen, X., Ji, J., Xu, Y., He, X., Zhang, H., Mo, Z., & Wang, F. (2023). Urinary exosomal prostate‐specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles. International Journal of Cancer, 152(8), 1719-1727. https://doi.org/10.1002/ijc.34388
Vancouver
Wei C, Chen X, Ji J, Xu Y, He X, Zhang H, et al. Urinary exosomal prostate‐specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles. International Journal of Cancer. 2023;152(8):1719-1727. doi:10.1002/ijc.34388
BibTeX
@article{Wei2023,
author = {Wei, Chunmeng and Chen, Xi and Ji, Jin and Xu, Yalong and He, Xing and Zhang, Huiyong and Mo, Zengnan and Wang, Fubo},
title = {Urinary exosomal prostate‐specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles},
journal = {International Journal of Cancer},
year = {2023},
volume = {152},
number = {8},
pages = {1719--1727},
doi = {10.1002/ijc.34388}
}
EUVIMED